3 ms·
A few comments, not even necessarily quibbles: Don't most people who get a heart attack die from their first one, with I assume little cost to the system? Of
by hga 16y ago
A few comments, not even necessarily quibbles:
Don't most people who get a heart attack die from their first one, with I assume little cost to the system? Of course the general improvements with so many problems means that more people are living long enough to get cancer....
The cost of cancer treatment is high enough that it probably swamps primary care, but one should still run the numbers. Large populations can have results that are non-intuitive to most, e.g. the increased costs of much preventive medicine due to the large numbers that need to be constantly screened to find a few true positives. If I didn't have a family history of aggressive prostate cancer (great-grandfather, 1 out of 6 uncles) I'd listen to my doctor's discouragement on getting yearly PSA testing (now that I'm 49, and yes, I know the test is rather iffy, how iffy I'll learn about after a baseline is established and/or before someone wants to do a biopsy (ouch)). Then again, I'll be paying the full cost of most of those tests.
WRT specialists and outcomes, raw full population outcomes aren't as useful for the individual considering options. In theory/in general the specialist will be able to go beyond the raw numbers and have a better idea of which option is the best bet.
I myself just can't understand the compliance problem ... although I do see the lack of appreciation of complex/the full system issues; even though I ended up going in the directions of chemistry and computers, my early medicine and biology learning was really beneficial.
I myself find the online guides to be useful (well, the Merck Manual is lots cheaper on-line for free :-), for me the biggest limitation in using them is not knowing what's normal. E.g. that tongue coating under these circumstances is no problem, maybe stop taking your antibiotic a couple of days early sort of thing. I know most people aren't in a position to get enough useful out of them to seriously "bend the cost curve", to draw this back to the main topic.
I'd never consider otitis media to be simple, it just obviously isn't, too much hidden, too much guesswork, especially since outcomes are so often ... not optimal (e.g. I lost some hearing in one ear due to one infection in the '70s, a girlfriend as well in the '80s).
Anyway, thanks for the intelligent discussion.
- carbocation 16y agoTo just respond to one point: even in the 1990s, mortality from acute MI was down to ~12%: (e.g., http://content.nejm.org/cgi/content/short/356/11/1099 http://content.nejm.org/cgi/content/short/356/11/1099 ). There are many sequelae of acute MI that are likely to be expensive in the long term (esp dilated cardiomyopathy). Then, there are the lifelong visits to cardiologists; cardiac imaging; and pharmacologic interventions.
- hga 16y agoThat's not the statistic I was referring to, which is is (or includes) the people who don't make it long enough to get admitted, i.e. those who are DOA.
- carbocation 16y agoAha. Not sure I've ever seen that number, which would involve coroner data, or sometimes simply be unavailable. Nevertheless, with ~200,000 people per year on Medicare alone having acute MI and surviving long enough to get to the hospital, we're still talking about a growing burden of MI survivors.
- deleted 16y ago[deleted]
- rianjs 16y agoYeah, those people DOA are cheaper than surviving, if you ignore what kind of wealth a person is likely to create by being alive. AFAIK, the latest numbers on acute MI survival are ~30%, and getting better in recent years due to the widespread adoption of the CHAMP protocol. Rates go up if things happen in a certain sequence of events, within certain prescribed timeframes. Medicare is beginning to compensate at a higher rate based on how well hospitals perform in cases like heart attacks. (And other common procedures/infection rates.) I'm not familiar with the specifics. I don't disagree on running the numbers on primary care, but any savings is likely to be trivial next to other areas of improvement. "Fixing" medmal is likely to be bigger than changing primary care, and the latest numbers on that (Amitabh Chandra, 2008, IIRC) are $50bn/yr. Medmal rates don't keep pace with the rest of health care inflation, so this is basically a one-time discount, and in terms of overall health spending, $50bn is only like 2%. In addition, even in states which have instituted some kind of tort reform, it hasn't changed how medicine is practiced, which is the ultimate cost driver. (Refs available, I'm just not at my primary computer.) It was very depressing to watch "health care reform" become "health insurance reform" sometime between late 2008 and summer 2009. The two aren't the same, and insurance reform won't due anything in the long run because demand for health care services is relatively inelastic, as you had mentioned, and I had alluded to before. Very depressing.